Looking at the filing, I can confirm this is Ardelyx, Inc.'s Form 10-Q for the quarterly period ended September 30, 2026, filed on the Nasdaq Global Market under ticker ARDX. The substantive disclosure content is sufficient to proceed.

Ardelyx, Inc. filed its quarterly report on Form 10-Q with the SEC for the period ended September 30, 2026, disclosing operational risks, product commercialization updates, and share count data as of October 27, 2026.

Key Highlights

  • Share count: 251,372,553 shares of common stock, par value $0.0001 per share, were issued and outstanding as of October 27, 2026, according to the filing.
  • XPHOZAH and Medicare: The filing states that XPHOZAH became part of the ESRD PPS on January 1, 2025, resulting in what the company described as "a negative and material impact" on XPHOZAH revenue in 2025.
  • Revenue dependence: The company disclosed substantial dependence on the successful commercialization of IBSRELA and noted no guarantee of sufficient market acceptance or adequate coverage and reimbursement.
  • Financing risk: The filing disclosed that additional financing may be required as the company invests in the growth of IBSRELA and XPHOZAH in the U.S. and builds a pipeline.
  • Large accelerated filer: Ardelyx indicated it is classified as a large accelerated filer as of the filing date.
  • Pipeline activity: The filing references evaluation of tenapanor for chronic idiopathic constipation and development of RDX10531 among clinical development activities.

Ardelyx Outlines Commercial and Financial Risks for IBSRELA and XPHOZAH in Q3 2026 Report

Ardelyx, Inc. (NASDAQ:ARDX) submitted its quarterly report covering the three-month period ended September 30, 2026. The filing identifies several key commercial and operational risks tied to the company's two approved products, IBSRELA and XPHOZAH, and describes ongoing pipeline development activities.

According to the filing, XPHOZAH's inclusion in the End-Stage Renal Disease Prospective Payment System (ESRD PPS) beginning January 1, 2025 means that "coverage for XPHOZAH for Medicare beneficiaries is not available under Medicare Part D." The company stated this resulted in what it called "a negative and material impact" on XPHOZAH revenue in 2025 and disclosed that "the continued lack of Medicare Part D coverage for XPHOZAH will result in a materially lower pace of revenue growth as compared to expectations before XPHOZAH became part of the ESRD PPS."

On IBSRELA, the company disclosed it is "substantially dependent on the successful commercialization" of that product and acknowledged no guarantee of maintaining market share or adequate reimbursement. The filing also noted that the company's operating activities may be restricted by covenants under a loan and security agreement with SLR, and that an event of default could require repayment of outstanding indebtedness, which the company stated "could have a materially adverse effect" on its business. Forward-looking statements in the filing are the company's own and subject to its cautionary language.

What Was Disclosed

Ardelyx filed its Form 10-Q for the quarter ended September 30, 2026, disclosing 251,372,553 shares outstanding as of October 27, 2026, material risks related to XPHOZAH's ESRD PPS inclusion, dependence on IBSRELA commercialization, and potential need for additional financing.